Abstracts Open Access
Copyright ©The Author(s) 1998. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 15, 1998; 4(Suppl2): 133-133
Published online Oct 15, 1998. doi: 10.3748/wjg.v4.iSuppl2.133
Effect of jianpiyiwei capsule on gastric secretory function, mucosal hexosamines and malonic dialdehyde concentrations in chronic atrophic gastritis in rats
Xue-Ying Shi, Feng-Zhi Zhao, Xin Dai, Jie Fang, Department of Pathology, Affiliated Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, China
Lian-Sheng Ma, Taiyuan Research and Treatment Center for Digestive Diseases, Taiyuan 030001, Shanxi Province, China
Xiu-Yun Dong, Department of Gastroenterology, Third School of Clinical Medicine, Beijing Medical University, Beijing 100083, China
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Xue-Ying Shi, Department of Pathology, Affiliated Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, China
Received: July 15, 1998
Revised: August 16, 1998
Accepted: September 10, 1998
Published online: October 15, 1998

Abstract

AIM: To study the theraputic mechanism of Jianpiyiwei capsula (JPYW) on chronic atrophic gastritis (CAG) in rats.

METHODS: The model of CAG was established in male wistar rats by synthetical method: a metallic spring was inserted into gastric pylorus sphincter. I week after operation, 50-60 °C hot paste which contains 15% NaCl were given twice a week orally for 15 wk, then 10 normal and 11 CAG model rats were killed and sampled to study: (1) The volume of gastric juice, (2) Gastric acidity and total output of gastric acid, (3) Activity of pepsin and its total out put, (4) Mucosal hexosamines and malonic dialdehyde (MDA) concentrations. The other CAG rats were treated with JPYW 1.5 g/kg/d or 4.5 g/kg/d, weimeisu (WMS) 0.6 g/kg/d, or distilled water (DW) respectively (n = 10 each group). After 12 wk, all the rats were killed and detected as above.

RESULTS: The volume and acidity of gastric juice, activity of pepsin, total output of acid and pepsin, mucosal hexosamines and MDA concentrations were 1.17 ± 0.29 mL/2h, 48.54 ± 16.95 mEq/L, 0.519 ± 0.115 unit/mL, 27.63 ± 8.07 μEq/h, 0.291 ± 0.058 unit/h, 4.82 ± 0 .74 μg/mg, tissue and 37.41 ± 4.91 μmol/100mg, tissue in model group whereas 2.08 ± 0.19, 96.80 ± 18.20, 0.843 ± 0.143, 100.11 ± 17.63, 0.873 ± 0.139, 6.85 ± 1.14 and 24.90 ± 2.48 in normal group , which were significantly different (P < 0.01). After 12 wk treatment, JPYW increased the volume and acidity of gastric juice, activity of pepsin, total output of acid and pepsin significantly (2.12 ± 0.86, 96.10 ± 30.91, 0.780 ± 0.168, 95.84 ± 31.05, and 0.779 ± 0.169 respectively in 4.5 g/kg group) as compared with DW group (1.37 ± 0.51, 50.20 ± 16.47, 0.515 ± 0.142, 32. 89 ± 11.73 and 0.327 ± 0.082 respectively) (P < 0.05 or P < 0.01). Furthermore, it decreased mucosal MDA concentration obviously (27.09 ± 3.98 in 4.5 g/kg group and 41.87 ± 4.27 in DW group) (P < 0.01). Although the hexosamines concentration was increased mildly (5.62 ± 0.93 in 4.5 g/kg group), it made no statistical difference to DW group (4.90 ± 0.84) (P > 0.05). WMS also had influence on above-mentioned indices, but was not as marked as JPYW 4.5 g/kg/d group, espically in total output of acid (56.54 ± 12.25) and pepsin (0.585 ± 0.100) and mucosal MDA concentration (31.43 ± 5.02) (comparing to 4.5 g/kg group, P < 0.05 or P < 0.01).

CONCLUSION: Improving the secretory function of gastric juice and preventing gastric mucosa from the injury of free radical may be one of the theraputic mechanism of JPYW on chronic atrophic gastritis.

Key Words: Gastritis, atrophic/therapy, Jianpiyiwei capsule, Hexosamines, Malonic dialdehyde, Disease models, animal



Footnotes

E- Editor: Li RF

$[References]